ApicHope Pharmaceutical Group Co., Ltd. (SHE:300723)
China · Delayed Price · Currency is CNY 37.08
+0.68 (1.87%)
Jul 21, 2026, 3:06 PM CST
SHE:300723 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 927.88 | 919.38 | 1,419 | 2,489 | 2,275 | 2,195 |
Other Revenue | 12.89 | 12.89 | 30.76 | 14.04 | 4.95 | 3.82 |
| 940.78 | 932.27 | 1,450 | 2,503 | 2,280 | 2,199 | |
Revenue Growth (YoY) | -21.88% | -35.72% | -42.07% | 9.79% | 3.68% | 31.26% |
Cost of Revenue | 400.69 | 416.76 | 576.21 | 481.98 | 300.2 | 321.98 |
Gross Profit | 540.08 | 515.51 | 874.02 | 2,021 | 1,980 | 1,877 |
Selling, General & Admin | 683.12 | 669.32 | 829.71 | 1,414 | 1,464 | 1,447 |
Research & Development | 158.66 | 157.25 | 312.09 | 301.37 | 189.78 | 142.32 |
Other Operating Expenses | 1.47 | 16.52 | 24.35 | 72.86 | 30.39 | 30.44 |
Operating Expenses | 842.67 | 842.52 | 1,167 | 1,792 | 1,685 | 1,621 |
Operating Income | -302.59 | -327.01 | -293.44 | 229.35 | 294.58 | 256.25 |
Interest Expense | -57.1 | -57.79 | -35.11 | -37.65 | -28.96 | -38.51 |
Interest & Investment Income | 564.47 | 6.35 | 3.72 | 11.71 | 8.46 | 28.96 |
Currency Exchange Gain (Loss) | -0.11 | -0.11 | 1.31 | -5.51 | 0.1 | -0.47 |
Other Non Operating Income (Expenses) | -51.63 | -1.03 | -3.28 | -1.27 | -1.78 | -6.41 |
EBT Excluding Unusual Items | 153.05 | -379.58 | -326.79 | 196.63 | 272.4 | 239.82 |
Impairment of Goodwill | - | - | -11.03 | - | - | - |
Gain (Loss) on Sale of Investments | -43.07 | -43.07 | -40.11 | -24.64 | -28.31 | 23.96 |
Gain (Loss) on Sale of Assets | -1.15 | -1.16 | 1.27 | 0.12 | 0.19 | -0.07 |
Asset Writedown | -4 | -4 | -15.85 | -1.02 | -0.45 | -1.34 |
Other Unusual Items | 58.28 | 58.36 | -253.2 | 73.09 | 82.59 | 100.4 |
Pretax Income | 163.12 | -369.45 | -645.71 | 244.19 | 326.41 | 362.77 |
Income Tax Expense | -29.59 | -22.99 | -79 | 92.39 | 64.32 | 69.36 |
Earnings From Continuing Operations | 192.71 | -346.46 | -566.71 | 151.8 | 262.1 | 293.41 |
Minority Interest in Earnings | 7.28 | 8.66 | 26.67 | 32.82 | 28.59 | 13.5 |
Net Income | 199.99 | -337.79 | -540.04 | 184.61 | 290.68 | 306.92 |
Net Income to Common | 199.99 | -337.79 | -540.04 | 184.61 | 290.68 | 306.92 |
Net Income Growth | - | - | - | -36.49% | -5.29% | 36.04% |
Shares Outstanding (Basic) | 452 | 452 | 452 | 452 | 429 | 422 |
Shares Outstanding (Diluted) | 452 | 452 | 452 | 452 | 433 | 424 |
Shares Change (YoY) | 0.02% | 0.01% | -0.00% | 4.43% | 1.94% | -2.20% |
EPS (Basic) | 0.44 | -0.75 | -1.20 | 0.41 | 0.68 | 0.73 |
EPS (Diluted) | 0.44 | -0.75 | -1.20 | 0.41 | 0.67 | 0.72 |
EPS Growth | - | - | - | -39.18% | -7.09% | 39.10% |
Free Cash Flow | -85.41 | -81.19 | -870.18 | 123.59 | -130.25 | -123.13 |
Free Cash Flow Per Share | -0.19 | -0.18 | -1.93 | 0.27 | -0.30 | -0.29 |
Dividend Per Share | - | - | - | 0.210 | 0.133 | 0.133 |
Dividend Growth | - | - | - | 57.54% | - | 43.95% |
Gross Margin | 57.41% | 55.30% | 60.27% | 80.75% | 86.83% | 85.36% |
Operating Margin | -32.16% | -35.08% | -20.23% | 9.16% | 12.92% | 11.65% |
Profit Margin | 21.26% | -36.23% | -37.24% | 7.37% | 12.75% | 13.96% |
Free Cash Flow Margin | -9.08% | -8.71% | -60.00% | 4.94% | -5.71% | -5.60% |
EBITDA | -108.4 | -135.05 | -110.38 | 387.34 | 366.46 | 305.79 |
EBITDA Margin | -11.52% | -14.49% | -7.61% | 15.47% | 16.07% | 13.91% |
D&A For EBITDA | 194.18 | 191.96 | 183.06 | 157.99 | 71.89 | 49.54 |
EBIT | -302.59 | -327.01 | -293.44 | 229.35 | 294.58 | 256.25 |
EBIT Margin | -32.16% | -35.08% | -20.23% | 9.16% | 12.92% | 11.65% |
Effective Tax Rate | - | - | - | 37.84% | 19.70% | 19.12% |
Revenue as Reported | 940.78 | 932.27 | 1,450 | 2,503 | 2,280 | 2,199 |